Sacubitril And Valsartan Tablet, Film Coated
Product Images NDC 50268-607

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Sacubitril And Valsartan (NDC 50268-607). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Avpak, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

1 (606 15)

This is not a valid text.*

FDA Label Image

1 (607 15)

This text provides information on a medication identified by its NDC code: 50268-607-15. The medication is Sacubitril and Valsartan Tablets containing 49 mg of sacubitril and 51 mg of valsartan. It consists of 50 tablets in a unit dose packaging of 5 x 10. The text mentions the dosage recommendation and storage instructions. The medication is available by prescription only.*

FDA Label Image

1 (608 13)

This is a description of Sacubitril and Valsartan Tablets with a strength of 97 mg/103 mg. The tablets are available in a unit dose pack of 30 tablets. The National Drug Code (NDC) for this product is 50268.608.13. Additionally, the text mentions dosage instructions and prescription details.*

FDA Label Image

1 (How Supplied)

This text provides information about a tablet medication called SacubltiValsartan containing 24mg/26mg in purple, 49mg/51mg in light yellow, and 97mg/103mg in light pink. The tablets come in different packagings (10 tablets per card, 5 or 6 cards per carton) and are dispensed in unit dose packaging for institutional use only.*

FDA Label Image

Figure-1 (Sacubitril Valsartan Figure 1)

This text provides the geometric mean ratio and 90% CI for various coadministered drugs including Furosemide, Warfarin, Digoxin, Carvedilol, Levonorgestrel, Ethinyl estradiol, Amlodipine, HeTZ, Metformin, Atorvastatin, and Sildenafil. It also mentions the change relative to reference.*

FDA Label Image

Figure-2 (Sacubitril Valsartan Figure 2)

FDA Label Image

Sacubitril-valsartan-figure-3.jpg (Sacubitril Valsartan Figure 3)

This text provides information on the time to first occurrence of cardiovascular death or heart failure hospitalizations in the PARADIGM-HF study. It includes data comparing the outcomes of patients treated with Sacubitril and Valsartan versus Enalapril. The text also presents data on the time to occurrence of cardiovascular death separately. The results show significant differences between the treatment groups in terms of these cardiovascular events. The text may be useful for healthcare professionals, researchers, or individuals interested in cardiovascular health and treatment outcomes in heart failure.*

FDA Label Image

Structure (Sacubitril Valsartan Structure)

FDA Label Image

Sacubitril-valsartanl-figure-4.jpg (Sacubitril Valsartanl Figure 4)

The text presents data on various subgroups including age, gender, weight, race, region, NYHA class, GFR, diabetes, blood pressure, ejection fraction, atrial fibrillation, NT-proBNP, hypertension, medication use, prior hospitalization, time since diagnosis, cause of heart failure, and presence of ICD. It also shows percentages of individuals within each category for treatment with Sacubitril and Valsartan as well as Enalapril, along with the Hazard Ratio. These statistics can be used to analyze the efficacy and impact of these medications on different demographic and health-related groups.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.